[HTML][HTML] Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells
K Murao, H Imachi, A Momoi, Y Sayo, H Hosokawa… - FEBS letters, 1999 - Elsevier
K Murao, H Imachi, A Momoi, Y Sayo, H Hosokawa, M Sato, T Ishida, J Takahara
FEBS letters, 1999•ElsevierThe chemokine monocyte chemoattractant protein-1 is a potent chemoattractant for
monocytes. Monocyte chemoattractant protein-1 is produced by vascular endothelial cells
during inflammatory diseases such as atherosclerosis. In this study, we examined the effects
of a thiazolidinedione on monocyte chemoattractant protein-1 expression in human vascular
endothelial cells. In human vascular endothelial cells, interleukin-1β and tumor necrosis
factor-α induced endogenous monocyte chemoattractant protein-1 protein secretion, mRNA …
monocytes. Monocyte chemoattractant protein-1 is produced by vascular endothelial cells
during inflammatory diseases such as atherosclerosis. In this study, we examined the effects
of a thiazolidinedione on monocyte chemoattractant protein-1 expression in human vascular
endothelial cells. In human vascular endothelial cells, interleukin-1β and tumor necrosis
factor-α induced endogenous monocyte chemoattractant protein-1 protein secretion, mRNA …
The chemokine monocyte chemoattractant protein-1 is a potent chemoattractant for monocytes. Monocyte chemoattractant protein-1 is produced by vascular endothelial cells during inflammatory diseases such as atherosclerosis. In this study, we examined the effects of a thiazolidinedione on monocyte chemoattractant protein-1 expression in human vascular endothelial cells. In human vascular endothelial cells, interleukin-1β and tumor necrosis factor-α induced endogenous monocyte chemoattractant protein-1 protein secretion, mRNA expression and promoter activity. The thiazolidinedione inhibited these effects. In summary, our results indicated that the suppression of the expression of monocyte chemoattractant protein-1 can be accomplished by thiazolidinedione treatment, raising the possibility that thiazolidinedione may be of therapeutic value in the treatment of diseases such as atherosclerosis.
Elsevier